List of accesskeys skip navigation

Clinical Specialties & Centres

Skip Navigation LinksHome > Clinical Specialties & Centres > Nuclear Medicine & PET

Nuclear Medicine and Molecular Imaging Overview

Our centre is one of the region's largest Nuclear Medicine departments and provides a comprehensive range of clinical services in radioisotope imaging and therapy. We are equipped with a Positron Emission Tomography (PET)/CT scanner with Time-of-Flight technology, two Single Photon Emission Computed Tomography (SPECT)/CT scanners and three gamma cameras. We also have seven inpatient beds and three outpatient clinic rooms for therapy consultations.  

The following are some of our subspecialties:

Nuclear Medicine Therapy

Radioiodine therapy

Radioiodine therapy is the oral administration of radioactive iodine (iodine-131) for the treatment of thyrotoxicosis (e.g. Graves’ disease, toxic multinodular goiter or toxic adenoma) and differentiated thyroid carcinomas.

Selective internal radiation therapy (SIRT)

Selective internal radiation therapy (SIRT) is a form of local radiation therapy for unresectable liver tumours. The procedure is performed in close coordination with interventional radiologists by delivering radioactive Yttrium-90 microspheres into the arteries supplying the tumours.

Peptide receptor radionuclide therapy (PRRT)

Peptide receptor radionuclide therapy (PRRT) is a molecular targeted therapy for inoperable metastatic well- or moderately-differentiated neuroendocrine tumours. It can also be used for other tumours with high somatostatin receptors expression. The treatment is performed with intravenous administration of radioactive somatostatin analogue (e.g. Lutetium-177 or Yttrium-90-labeled radiopeptide).

Iodine-131 MIBG therapy

Iodine-131 MIBG therapy is a systemically administered radiotherapy used in the treatment of inoperable metastatic neuroectodermal tumours such as pheochromocytoma, paraganglioma, neuroblastoma, medullary thyroid cancer and carcinoid tumors.


Radiosynovectomy is a radionuclide therapy to treat chronic joint synovitis or synovial processes. The majority of our referrals are of chronic inflammatory arthritis e.g. rheumatoid arthritis, and haemophilic synovitis. The treatment is performed by intra-articular injection of the colloidal form of Yttrium-90, Rhenium-186 and Erbium-169.

Bone pain palliative therapy

Bone-seeking radiopharmaceuticals (e.g. Strontium-89 chloride, Samarium-153, Rhenium-188) are used for the palliation of pain from bone metastases.

Radio-labelled (e.g. Yttrium-90, Iodine-131)  anti-CD20 monoclonal antibody therapy for refractory/relapsed low-grade non-Hodgkin's lymphoma 


Nuclear Medicine Imaging

Positron Emission Tomography (PET)

Advanced imaging technique for oncology, cardiology and neurology. State-of-the-art fusion PET/CT scanner provides functional information with anatomic correlation. Current radiotracers include:-

  • Fluorine-18 FDG for tumour and infection imaging, to assess myocardial viability and for the work-up of early dementia and refractory epilepsy
  • Gallium-68 DOTATATE and analogues for neuroendocrine and other somatostatin receptor positive tumours
  • Fluorine-18 Choline for brain and prostate tumours

Routine Nuclear Medicine Scan

  • Bone scintigraphy for assessment of bone metastases and other skeletal abnormalities. Bone mineral densitometry - for assessment of bone mass and evaluation of osteopenia and osteoporosis.
  • Nuclear cardiology with myocardial perfusion imaging and radionuclide gated-ventriculography.
  • Brain perfusion imaging for cerebrovascular insufficiency, epilepsy and brain death.
  • Renal imaging including renography, captopril studies and renal cortical imaging.
  • Thyroid scintigraphy for assessment of thyroid nodules and thyroid function.
  • Parathyroid scintigraphy for localisation of parathyroid adenomas in hyperparathyroidism.
  • Gastrointestinal studies e.g. radionuclide tagged-red blood cells scan, Meckel's scan, hepatobiliary scan, gastric emptying study and peritoneal scan.
  • Lung studies including V/Q scan for pulmonary embolism and lung perfusion scan for lung function quantification prior to surgery.
  • Iodine-131 MIBG and Indium-111octreotide imaging for neuroendocrine tumours.
  • Lymphoscintigraphy for lymphoedema.
  • Sentinel node scintigraphy and radionuclide occult lesion localisation (ROLL) for breast cancers.
  • Labelled white-blood cells scan for infection localisation.

Non-Imaging Nuclear Medicine Tests

  • Chromium-51 EDTA renal clearance study for evaluation of glomerular filtration rate
  • Helicobacter pylori C-14 breath test (Urea Breath Test)
  • Hormone assays for assessing thyroid, fertility and metabolic functions (available from our Endocrine Laboratories). 
Staff MembersSub-Specialty
Head and Senior Consultant
Assoc Prof Ng Chee Eng David MBBS, MRCP (UK), FAMSNuclear Medicine
Senior Consultant, Director, Endocrine Laboratories
Dr Aw Swee Eng MBBS, PhD (Chem Path)(Lond), FRCPath (Lond), FAMSClinical Biochemistry, Endocrinology
Senior Consultant
Dr Lam Wing Chuen, Winnie MBBS, FRCR (UK), FAMSNuclear Medicine and PET
Dr Wong Wai Yin MBBS, FRCR (UK), FAMSNuclear Medicine and PET
Dr Khor Yiu Ming MBBS (Singapore), MRCP(UK), MMedNuclear Medicine and PET
Senior Consultant
Dr Loke Siu Hoong Kelvin MBBS, FAMS, MRCP (UK)Nuclear Medicine and PET
Dr Sumbul Zaheer MBBS (Aligarh), MRCP (UK)Nuclear Medicine and PET
Dr Tong Kian Ti, Aaron MBBS, MRCP(UK), MMed (Int Med), FAMSNuclear Medicine & PET
Dr Yan Xuexian MD, ABNMNuclear Medicine and PET
Dr Thang Sue Ping MBChB (Edinburgh), MRCP(UK)Nuclear Medicine & PET
Dr Xie WanYing MBBS, FRCR, MMedNuclear Medicine and PET
 Butch M Magsombol MD (Far Eastern), Dip (Nuclear Med) (AMS)Nuclear Medicine
Dr Bharadwaj Pushan MBBS (India), CCST (Nuclear Medicine, UK), FRCP (UK), DCBNC (USA), FEBNM (Vienna), MSc (Cardiology, UK)Thyroid Disease and Nuclear Cardiology


Tel :  6326 5357
(for PET appointment)
Fax:  6326 5449

Tel :  6321 4203 /  6321 3838 (for other appointments)
Fax : 6326 5338


Department Office:

Academia, Level 4
Tel: 6326 6040
Fax: 6224 0938
(for departmental matters only)

Last Modified Date :01 Feb 2018